Abstract
Extracellular vesicles (EV) can be produced as part of pathology and physiology with increased amounts in pathological conditions. EVs can carry and transfer cargo such as proteins, nucleic acids, and lipids to target cells and mediate intercellular communication resulting in modulation of gene expression, signaling pathways, and phenotype of recipient cells. EVs greatly influence the extracellular environment and the immune response. Their immunomodulatory properties are crucial in rheumatoid arthritis (RA), a condition marked by dysregulated immune response. EVs can modulate the functions of innate and adaptive immune cells in RA pathogenesis. Differentially expressed EV-associated molecules in RA, such as microRNAs (miRNAs), long-noncoding RNAs (lncRNAs), messenger RNAs (mRNAs) and proteins are promising markers to diagnose the disease. miRNA, lncRNA, and circular RNA (circRNA) cargos in EV regulate inflammation and the pathogenic functions of RA fibroblast-like synoviocytes (RA-FLS). Downregulated molecules in RA tissue and drugs can be encapsulated in EVs for RA therapy. This review provides an updated overview of EVs’ immunomodulatory, diagnostic, and therapeutic roles, particularly emphasizing mesenchymal stem cell-derived EVs (MSC-EVs).
1 Introduction
Extracellular vesicles (EVs) are membrane-enclosed particles released by eukaryotic and prokaryotic cells as part of physiological and pathological processes with increased release under pathological conditions (–). EVs can carry various biomolecules, including proteins, nucleic acids, and lipids to the extracellular environment facilitating the transfer of their cargo to the recipient cells (, ). Recent evidence suggests that EVs may also contain mitochondria which control the epigenetics of target cells and organs ().
The lipid bilayer of EVs encloses and protects their contents from the external environment (). EVs vary in size from nanoscale exosomes to larger microvesicles and can be secreted by virtually all cell types (). They are present in various body fluids including cerebrospinal fluid (CSF) (), breast milk (), synovial fluid (SF) (), saliva (), urine () and blood (). Initially, EVs were considered mere cellular waste, leading to their limited investigation until recent years ().
Traditionally, EVs were classified based on particle size and biogenesis into exosomes, microvesicles, and apoptotic bodies (, ). Exosomes, the smallest EVs, are formed through the inward budding of the plasma membrane during endosome generation, which matures into multivesicular bodies (MVBs) or late endosomes (, ). These MVBs either fuse with cell membrane to release exosomes or merge with lysosomes for degradation (, ). Microvesicles, (also called ectosomes) are generated through the outward budding and fission of the plasma membrane (, ), while apoptotic bodies, the largest EVs, are produced during programmed cell death and contain both cytoplasmic and nuclear materials (, ). However, no definitive molecular markers exist to distinguish these categories ().
Given the limitations of biogenesis-based classification, the International Society for EVs recommended avoiding this terminology unless universal molecular markers and effective separation techniques are available. In its 2023 position paper, “Minimal Information for Studies of EVs (MISEV 2023),” the Society advocated using the general term “extracellular vesicles” and proposed size-based nomenclature, such as “small EVs (sEV)” for particles smaller than 200 nm and “large EVs (LEV)” for those larger than 200 nm ().
EVs significantly impact the extracellular environment and immune responses (, ). They facilitate intercellular communication by transferring functional components or inducing receptor-mediated signaling (). The surface proteins of EVs and their cargo can modulate gene expression, signaling pathways, and the phenotypes of target cells (). EVs, produced endogenously, have advantages over synthetic nanoparticles and viral vectors, including higher biocompatibility, lower immunogenicity, and better evasion of phagocytosis (). Moreover, their ability to cross biological barriers, such as the placental, blood-brain, blood-tumor, and blood-testis barriers, makes EVs promising tools for drug delivery (, , ). EVs have shown significant potential in the detection and treatment of autoimmune diseases including rheumatoid arthritis (RA) (), multiple sclerosis (), and type 1 diabetes ().
RA is among the most prevalent chronic inflammatory disorders, affecting approximately 0.5% of the population globally (, ). This long-lasting autoimmune disease leads to the progressive destruction of joints. Despite advancements with disease-modifying antirheumatic drugs (DMARDs), treatment remains inconsistent, with 30-40% of patients discontinuing DMARDs due to ineffectiveness or side effects (–). Blocking tumor necrosis factor-α (TNF-α) helps reduce joint inflammation, prevent structural damage, and enhance the quality of life in 60-70% of RA patients. However, since some individuals don not respond to this therapy, alternative treatment options are necessary (). Given the limitations of current treatments, researchers are increasingly exploring biotherapies, including EVs (). In this review, we discuss what is presently known about the roles of EVs in RA’s immunomodulation, diagnosis, and therapeutic potential, with a special emphasis on mesenchymal stem cell (MSC)-derived EVs.
2 EV-induced immunomodulation in RA
Various immune cells, including T cells (), B cells (), macrophages (), and mast cells () play a role in the progression of RA, with macrophages and T cell subsets playing particularly significant roles (–). T helper 1 (Th1) cells stimulate the production of interferon-γ (IFN-γ), TNF-α, and interleukin 2 (IL-2), contributing to cartilage damage and bone erosion, while, Th17 cells release IL-22, promoting the growth of synovial fibroblasts (). B cells generate autoantibodies and drive autoimmune responses through the production of rheumatoid factor (). Macrophages provide proinflammatory cytokines such as TNF- α and IL-1β ().
New RA therapies have been proposed that focus on regulating the local immune response and promoting antigen-specific immune tolerance (). EVs derived from MSC, neutrophils, granulocytic myeloid-derived suppressor cells (G-MDSCs), Dendritic cells (DC), and macrophages modulate the immune response within the inflammatory microenvironment of injured cartilage ().
The type and condition of the source cell determine the influence of EVs on the immune response (). MSC-derived EVs possess strong immunomodulatory properties, and their effectiveness is linked to their uptake by immune cells (, ). These EVs can regulate both innate and adaptive immune functions, reducing abnormal inflammation while ensuring safety in the surrounding microenvironment (–). This makes them a promising option for treating inflammatory diseases ().
2.1 EV-induced innate immune modulation in RA
EVs influence the functions of innate immune cells, impacting processes like differentiation, activation, migration, and cytokine production, as well as their abilities in cytolysis, phagocytosis, and antigen transfer (). Macrophages are crucial innate immune cells involved in the pathogenesis of RA (, ). In RA patients, there is an increase in pro-inflammatory M1 macrophages and a reduction in anti-inflammatory M2 macrophages (). M1 macrophages secrete pro-inflammatory substances whereas M2 macrophages release anti-inflammatory agents (). EVs can influence macrophage function by transferring regulatory miRNAs and proteins modulating inflammatory responses by affecting toll-like receptor 4 (TLR4) signaling and cytokine production (, ). M2 macrophage-derived EVs transfer proteins which can polarize macrophage to M2 phenotypes (). Additionally, neutrophil-derived microvesicles can boost anti-inflammatory factors like transforming growth factor-β (TGF-β) and prevent inflammatory activation of synoviocytes in arthritis models ().
MSC-derived EVs have been shown to promote M2 macrophages while reducing pro-inflammatory M1 macrophages in the synovial tissue of mice with collagen-induced arthritis (CIA) (). Additionally, bone marrow MSC-derived EVs (BMSC-EVs) were found to inhibit the secretion of inflammatory cytokines including IL-1β, TNF-α, and IL-18 in macrophages from mice with RA (). In vitro studies indicated that MSC-EVs can prevent DC maturation by downregulating the expression of CD80, CD83, and CD38, decreasing IL-6 and IL-12p70 secretion, and increasing TGF-β production. These findings suggest that MSC-EVs could be a promising therapeutic approach in mitigating autoimmune diseases such as RA by modulating dendritic cell function ().
2.2 EV-induced adaptive immune modulation in RA
In RA, dysregulated immune responses activate auto-reactive T and B cells, leading to their proliferation and differentiation into pathogenic cells that produce autoantibodies, thereby driving joint inflammation and degradation ().
EVs isolated from plasma of RA patients suppress early B cell activation in RA by downregulating the expression of activation markers like CD69+ and CD86+, and by inhibiting intracellular signaling pathways that are essential for B cell proliferation, function, and survival results (). BMSCs and G-MDSCs release EVs that regulate B cell differentiation by promoting CD19+IL-10+ regulatory B (B reg) cells and reducing plasmablast phenotypes in the lymph node of mice with CIA (, ) (Figure 1).
Figure 1
Human gingival mesenchymal stem cell-derived EVs (GMSC-EVs) regulate CD4+ T cell subpopulations by increasing regulatory T (T reg) cells and decreasing Th1 and Th17 cells in the CIA model. Experiments conducted both in vivo and in vitro demonstrated that GMSC-EVs induce upregulation of anti-inflammatory cytokine (IL-10) and downregulation of proinflammatory cytokines including IFN-γ, IL-17A, TNF-α, and IL-6 (). These EVs carry miR-148a-3p, which is responsible for immunomodulatory effects by directly targeting IKKB (inhibitor of nuclear factor kappa B kinase) in T cells (). G-MDSC-derived EVs demonstrated a similar immunosuppressive effect on CD4 T cells in CIA mice. G-MDSC-EV cargos (miR-29a-3p and miR-93-5p) suppress the differentiation of Th1 and Th2 cells by targeting T-bet and signal transducer and activator of transcription 3 (STAT3), correspondingly ().
EVs derived from human umbilical cord stem cells (hUCMSC-EVs) suppress T lymphocyte proliferation and induce apoptosis along with upregulation of forkhead box p3 (FoxP3) and downregulation of retinoic-related orphan receptor (RORγt) in the spleen of CIA mice (, ). These types of EVs demonstrated a Th1/Th17 and T reg cell balance accompanied by reduced levels of IL-17 and enhanced TGF-β and IL-10 in CIA mice (–). MSC-EVs derived from adipose tissue also modulate activated T cells by down-regulating miR23a-3p, which post-transcriptionally regulates TGF-β receptor 2 (TGFBR2) and increases the expression of FoxP3 (). Furthermore, MSC-EV regulates the proliferation of activated T cells by inducing cell cycle arrest via upregulation of P27kip1 expression and downregulation of cdk2 expression (). On the other hand, both CD4 and CD8 T cell proliferation were not affected in the presence of EVs derived from bone marrow MSC. However, an indirect inhibitory effect was observed through T reg cell induction resulting in a reduction of CD4 and CD8 T cells ().
Research suggested that manipulating MSC-EVs could enhance a balance among Th cells and reduce the production of proinflammatory cytokines. EVs isolated from miR-146a transduced MSC resulted in upregulating FoxP3, TGFβ, and IL-10 and downregulating IFN-γ in CIA models (, ). More importantly, pro-inflammatory cytokine-priming of MSC-EVs does not affect its immunosuppressive potential (, , ). Moreover, EVs derived from interferon-β (IFN-β)-primed MSCs down-regulated the expression of RA-associated cytokines (IL-4, GM-CSF, IFN-γ, IL-2, TNF-α) and diminished CD4+ T-cell polyfunctionality in RA CD4+ T cells (). Immortalized adipose tissue-derived MSCs primed with serum from RA disease conditions generate EVs that boost TGF-β1 production, promote Th2 induction, and facilitate M2 polarization, reducing inflammatory cytokines in CIA mice ().
Under normoxic conditions (21% O2, 5% CO2), MSC-derived EVs promoted T reg cell phenotypes and reduced CD4+ T cell polarization toward Th17 phenotypes, demonstrating their immunomodulatory effects in an antigen-induced arthritis model (). Under hypoxic conditions, EVs derived from polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) suppress the proliferation of CD4+ T cells in the CIA mouse model (). In contrast, synovial fibroblast-derived EVs in a hypoxic environment, reduce T reg cells and promote polarization of Th17 cells. Elevated levels of miR-424 under this condition downregulate FoxP3, thereby worsening RA ().
EVs generated from TGF-β primed T reg cells effectively mitigated the Th17 and Treg cells imbalance in arthritic mice and regulated the inflammatory responses of recipient T cells via miR-449a-5p-dependent mechanism (). Microvesicle mimetics (MVM) isolated from endotoxin-tolerant DCs possessed a bioactive miR155-3p and exhibited remarkable immunosuppression by inducing T reg and anti-inflammatory macrophages in RA models (). In addition, in the RA microenvironment, EVs containing programmed death receptor 1 (PD-1) facilitate T cell exhaustion in the joints (). Moreover, in RA patients, SF EVs expressing gangliosides (GD3), were associated with immunosuppression by inhibiting T cell activation after stimulation via TCR. This suggests that immunosuppressive EVs in the synovial fluid serve as a novel immune checkpoint for T cells ().
3 EVs as a diagnostic marker of RA
The potential role of EVs in discovering specific biomarkers to diagnose various autoimmune diseases has been highlighted (). The quantity of EVs is notably higher in the plasma and synovial fluid of individuals with RA than in healthy controls (). EVs are recognized for containing distinct proteins that reflect the characteristics of their originating cells (). Differentially expressed miRNA and lncRNAs containing EVs are also associated with RA’s immune response and metabolic process (). By comprehending the variety of their contents and associated targets, it could be feasible to diagnose RA and other autoimmune diseases (93).
3.1 EV microRNAs (EV-miRNA) as a diagnostic marker of RA
miRNAs are short non-coding RNAs that play a role in cell signaling, intracellular communication, regulation of gene expression, and chronic inflammation and immune responses (94, 95). They are key regulators of skeletal remodeling and play a role in the development of RA (96). SF from joints exhibiting high-grade inflammation had 3.5 times more miRNA-positive EVs per ml than normal levels. Analysis of the most prevalent miRNAs indicated that they negatively regulate several inflammation-related genes, including STAT3, which play a pro-inflammatory role in RA (97).
While various EV-miRNAs have been investigated for HBV-related tumor detection (98), several studies have shown promising results in using EV-associated miRNAs for RA diagnosis (Table 1). Dysregulated RNAs in sEVs derived from FLS associated with arthritis in mice models were highlighted as a potential biomarker for RA (99). The miRNA content of EVs, such as miR-212-3p, miR-338-5p, miR-410-3p, and miR-537, showed elevated levels in early RA during methotrexate (MTX) treatment, suggesting their potential as diagnostic and prognostic biomarkers (100). miRNA cargos such as (hsa-miR-335-5p and hsa-miR-486-5p) were higher in the peripheral blood of RA patients than in healthy controls and associated with disease activity (101). Furthermore, miRNA-1915-3p containing EVs were elevated in the clinical remission group of Korean RA and negatively correlated with serum C-reactive proteins (CRP) levels and may be useful to indicate RA disease activity (102).
Table 1
| EV associated biomarker | Biomolecule | EV source | Detection method | Expression level | Ref. |
|---|---|---|---|---|---|
| miR-204-5p | miRNA | plasma | qRT-PCR | downregulated | (127) |
| DPYSL3 | protein | CD4+T cells | Proteomics | upregulated | (114) |
| PSME1 | CD4+T cells | Proteomics | downregulated | ||
| miR-221 | miRNA | synovial fluid | qRT-PCR | upregulated | (99) |
| miR-45a & miR-25-3p | miRNA | serum | qRT-PCR | upregulated | (105) |
| hsa-miR-335-5p | miRNA | blood | qRT-PCR | upregulated | (101) |
| hsa-miR-486-5p | |||||
| TCONS_I2_00013502 | lncRNA | serum | qRT-PCR | upregulated | (109) |
| ENST00000363624 | lncRNA | serum | qRT-PCR | downregulated | |
| NONHSAT193357.1 | lncRNA | serum | qRT- PCR | downregulated | () |
| CCL5 | mRNA | serum | qRT- PCR | downregulated | |
| MPIG6B | mRNA | serum | qRT- PCR | downregulated | |
| IgM | protein | Plasma | ELISA | upregulated | (115) |
| SNHG6 | lncRNA | plasma | qRT-PCR | upregulated | (110) |
| RPS18P9 | lncRNA | plasma | qRT-PCR | upregulated | |
| CXXC4-AS1 | lncRNA | plasma | qRT-PCR | downregulated | |
| ENST00000433825.1 | lncRNA | synovial fluid | qRT-PCR | upregulated | (107) |
| miR-6089 | miRNA | serum | qRT-PCR | downregulated | () |
| miR-144-3p | miRNA | plasma | qRT-PCR | downregulated | (128) |
| miR-30b-5p | miRNA | plasma | qRT-PCR | downregulated | |
| miR-885-5p | miRNA | serum | qRT-PCR | upregulated | (129) |
Expression of various miRNA, lncRNA, mRNA, and proteins in EV during RA.
CCL5; chemokine c-c motif ligand 5, DPYSL3; dihydropyrimidinase-related protein 3, IgM; Immunoglobulin M, lncRNA; long noncoding RNA, MPIG6B; megakaryocyte and platelet inhibitory Receptor G6b, miRNA; microRNA, PSME1; proteasome activator complex subunit 1, qRT-PCR; quantitative real-time PCR, RPS18P9; ribosomal protein s18 pseudogene 9, SNHG6; small nucleolar RNA host gene 6.
The bold text indicates Rheumatoid arthritis (RA) biomarkers associated with extracellular vesicles (EVs).
Differentially expressed miRNAs linked to RA pathogenesis, such as miR-155-5p, miR-146a-5p, miR-323a-5p, and miR-1307-3p, were found in EVs derived from RA synovial fibroblast cell lines after TNF-α stimulation (103). Based on the serum EV expression profiles, patients with RA exhibited elevated levels of variably expressed miR-125a-5p, miR-130b-3p, miR-151a-5p, miR-301a-3p, and miR-324-5p (104). A combination of sEV miRNAs and soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) diagnosed early RA with a sensitivity of 85.7% and a specificity of 100% (105) (Table 1).
3.2 EV-Long noncoding RNAs (EV-lncRNA) as a diagnostic marker of RA
Long non-coding RNAs (lncRNAs) represent a new category of non-coding RNAs that do not produce proteins (106). The expression profiling of lncRNAs in EVs obtained from the synovial fluid of RA demonstrated significant differences when compared to osteoarthritis (OA) and gout (107). The serum sEV lncRNA profiles in patients with RA were also distinct from those of healthy controls and patients with OA ().
The expression of circular RNAs (circRNAs), such as circFTO, is elevated in EVs derived directly from FLS of RA patients. These EVs promote RA progression by suppressing chondrocyte growth and migration while enhancing apoptosis and catabolism (108). Variably expressed lncRNAs in serum EVs from RA patients showed both upregulation and downregulation (109). lncRNAs found in plasma EVs from individuals with RA exhibit distinct expression profiles, including several lncRNAs that may serve as diagnostic biomarkers. The receiver operating characteristics curve (ROC), which is used to evaluate the diagnostic accuracy of biomarkers, revealed that lncRNAs including SNHG6, RPS18P9, and CXXC4-AS1 demonstrated an area under the curve (AUC) ranges of 0.847-0.994 in diagnosing RA (110).
3.3 EV-associated protein and mRNAs as diagnostic markers of RA
Analysis of differentially expressed proteins in EVs from SF revealed that stromelysin-1 and pregnancy zone protein (PZP) were among the highly expressed proteins in RA as compared to OA (111). Proteomic analysis found that EVs from RA-FLS had higher pentraxin (PTX3) and lower proteasome 20S subunit beta 5 (PSMB5) levels than OA patients, promoting macrophage migration and RA progression (112). Lipid binding protein (LBP) and monocyte differentiation antigen (CD14) were also upregulated in EVs. Notably, the interaction of these proteins may play a role in nuclear factor kappa B (NF-κB) signaling, promoting the expression of IL-8 and TNF-α, which could contribute to the development of RA and serve as potential biomarkers for its diagnosis (113).
Differentially expressed proteins were identified as both upregulated and downregulated in the CD4+ T cell-derived EVs of RA patients, suggesting that these proteins could act as potential biomarkers for RA (114). The levels of CD3+ CD4+ protein containing EVs in the serum of RA patients are elevated, whereas the levels of CD3+CD8+ EVs are reduced, reflecting that total CD4+ T cells are dominant over CD8+ T cells ().
In a subset of seropositive RA patients, rheumatoid factor immunoglobulin M (IgM-RF) was found on plasma EVs and associated with increased disease activity. This discovery suggests a potential biological factor that could explain the discrepancy between global disease activity assessments and the counts of tender and swollen joints (115). Elevated levels of circulating EVs testing positive for immunoglobulin G (IgG), IgM, CD41a, and citrulline were also observed in seropositive RA patients (116). Profiling of plasma EVs identifies proteins significantly linked to the patient’s global disease activity (PGA) in RA. Notably, actin-cytoskeleton linker proteins, including ezrin and moesin, correlate positively with PGA (117).
Circulating EVs express elevated levels of posttranslational modified proteins such as citrullinated proteins and contribute to the pathogenesis of RA by triggering autoimmunity (118). EVs containing major histocompatibility complex class II (MHC II) molecules can be loaded with citrullinated peptide antigens and presented to T cells (119). These peptide antigens can be recognized by autoreactive T cells and trigger the production of anticitrullinated protein antibodies, a key hallmark for RA (120, 121). Autophagy appears to contribute to the generation of citrullinated peptide and EVs in RA (122, 123). It also promotes the citrullinated peptide-MHC II interaction in RA synovial fibroblasts (124). The autophagic system releases cellular content through EVs (122, 125), which can propagate autoantigens and potentially contribute to joint inflammation in RA patients (126) (Figure 2).
Figure 2
The serum sEV mRNA profiles in RA patients differed from those of healthy controls and individuals with OA. A combination of differentially expressed mRNAs achieved an AUC of 0.845 in distinguishing RA from OA () (Table 1).
4 EV as a promising therapeutic agent for RA
EVs have gained interest as a potential cell-free therapy due to their low immunogenicity, tumorigenicity, and ease of management (, 130). They are considered a promising approach for treating RA and may be used as drug delivery vehicles, including as nanocarriers to enhance the therapeutic effect of glucocorticoids in RA treatment (93, 131–133).
Research indicates that EVs from bone marrow macrophages lacking miR-100-5p exacerbate RA progression. In contrast, EVs overexpressing miR-100-5p help reduce inflammation and inhibit the proliferation of RA-FLS in RA (134). EVs from M2 macrophages, loaded with plasmid DNA for IL-10 and betamethasone sodium phosphate, reduced RA inflammation by promoting M1-to-M2 polarization and enhancing anti-inflammatory cytokine secretion (135). IL-4 delivered via small EVs (sEVs) showed a stronger anti-inflammatory effect in mice with CIA than soluble IL-4, indicating greater immunomodulatory potential (136). Additionally, macrophage-derived EVs loaded with IL-10 could be targeted to inflamed areas using noninvasive ultrasound, offering a promising strategy for macrophage polarization to M2 phenotypes in RA treatment (137).
A hybrid nanovesicle (HNV) combining an M1 macrophage membrane with exosome-mimic nanovesicles from M2 macrophages, loaded with black phosphorus sheets, can eliminate inflammatory cells in RA through near-infrared irradiation (138). Apoptotic EVs from macrophages and osteoclasts show synergistic effects in RA joints by reducing synovial inflammation, restoring cartilage, reversing bone erosion, and preserving joint structure (139). Additionally, EVs from immunosuppressive DCs can inhibit the onset and reduce the severity of CIA in mouse models (140). EVs from Indoleamine 2,3-dioxygenase-expressing DCs also demonstrated anti-inflammatory effects in murine models with CIA (141).
EVs engineered to carry super repressor IkB (srIkB), an NF-κB inhibitor, significantly reduced inflammatory cytokine production in PBMCs and synovial fibroblast mononuclear cells (SFMCs) collected from RA patients. Moreover, srIkB EVs treatment showed notable decreases in inflammation, cartilage degradation, and bone erosion in the joint tissues of CIA mice ().
MSCs are a promising alternative for treating RA due to their immunomodulatory capabilities (142, 143) (Table 2). More importantly, the potential of EVs derived from MSCs in immunomodulation and tissue regeneration presents a novel concept for treating rheumatism (, 144, 145). MSC EVs transfer non-coding RNAs that modulate crucial signaling pathways in the development of RA (). Different miRNA and lncRNA cargos delivered by MSC-EVs influence RA disorders through the NF-κB and MAPK pathways (). Moreover, EVs released from MSCs have been identified as important signaling molecules that play a role in the healing process by modulating the local microenvironment with anti-inflammatory properties (146, 147).
Table 2
| EV cargo | Source cell | Target cell | Target molecule | Function | Ref. |
|---|---|---|---|---|---|
| miR-451a | UCMSC | RA Synovial Fibroblast | ATF2 | • Inhibition of RA-FLS proliferation, migration, and invasion | (152) |
| miR150-5p | BMSC | FLS | MMP4 & VEGF | • Decreased joint damage • Inhibit synovial cell hyperplasia and angiogenesis | (159) |
| miR-21 | BMSC | FLS | TET1 | • Reduce inflammatory cytokine secretion • Alleviate RA progression | (160) |
| circFBXW7 (circ RNA) | BMSC | FLS | miR-216a-3p | • Inhibited proliferation, migration, and inflammation in RA-FLSs • Inhibit RA damage | (161) |
| miR-205-5p | BMSC | RA-FLS | MDM2 | • Suppresses inflammation | (162) |
| miR-320a | BMSC | FLS | CXCL9 | • Reduced activation, migration, and invasion of RA-FLS • Reduce severity of arthritis | (163) |
| miR-378a-5p | BMSC | HSMECs | IRF1 | • Promotes proliferation, migration and angiogenesis of HSMEC | (148) |
| circEDIL3(circ RNA) | SMSC | FLS | miR-485–3p | • Decreased VEGF expression • Reduced severity of arthritis | (164) |
| miR-106b | Synovial fibroblast | Chondrocytes | PDK4 | • Suppression of chondrocyte proliferation and migration • Reduces RA progression | (165) |
| miR-433-3p | SMSC-EV | FLS | FOXO1 | • Inhibition of VEGF expression • Reduced severity of arthritis | (166) |
| TRAF1-4:1(lncRNA) | RA-FLS | Chondrocytes | miR-27a-3p | • Inhibit chondrocyte proliferation and migration • Breakdown ECM | (167) |
| FGL1 | BMSC | RA-FLS | NA | • Impair RA-FLS viability • Enhance RA-FLS apoptosis | (168) |
| miR223 | BMSC | Macrophage | NLRP3 | • Suppression of inflammation | () |
| miR-486-5p | RA-FLS | Osteoblast | Tob1 | • Enhance osteoblast differentiation | (169) |
| miR-148a-3p | GMSC | FLS | IKKB | • Inhibit migration of RA-FLS • Inhibit cartilage degradation | () |
| miR-140-3p | UCMSC | FLS | SGK1 | • Reduced joint injury | (170) |
| miR-124a | MSC | FLS | NA | • Promote apoptosis of FLS cell • Inhibit proliferation and migration of FLS cell line | (171) |
Therapeutic roles of various miRNA, lncRNA, and circRNA EV cargos in RA.
ATF2; activating transcription factor 2, BMDM; bone marrow-derived macrophage, CXCL 9; chemokine ligand 9, circRNA; circular RNA, ECM; extracellular matrix, FGL1; fibrinogen-like protein 1, FLS; Fibroblast-like synoviocytes, FOXO1; forkhead box o1, GMSC; gingival mesenchymal stem cell, HSMECs; human synovial microvascular endothelial cells, IKKB; inhibitor of nuclear factor kappa B kinase, IRF1; Interferon regulatory factor 1, MMPR; matrix metalloproteinase, MDM2; mouse double minute 2, MSC; mesenchymal stem cell, NA; not available, NLRP3; NOD-, LRR- and pyrin domain-containing protein 3, PDK4; pyruvate dehydrogenase kinase 4, RA-FLS; rheumatoid arthritis-fibroblast like synoviocytes, SGK1; serum and glucocorticoid-inducible kinase 1, SMSC; synovial mesenchymal stem cell, TET1; Tet methylcytosine dioxygenase 1, Tob1; Transducer Of ERBB2, 1, TRAF1-4:1; tumor necrosis factor-associated factor 1, UCMSCs; umbilical cord mesenchymal stem cells, VEGF; vascular endothelial growth factor.
The bold text indicates Therapeutic biological molecules carried by EVs.
EVs derived from human embryonic stem cells MSCs reduce inflammation, cartilage degradation, and bone loss, primarily through the modulation of M2 macrophages in arthritis mouse models (). Additionally, miR-378a-5p from BMSC-derived EVs enhances the proliferation, migration, and angiogenesis of human synovial microvascular endothelial cells by suppressing the IRF1/STAT1 pathway, contributing to the prevention of RA (148).
FLS are crucial in the progression of RA, making them a target for potential treatments (149, 150). EVs from human GMSC have been shown to reduce arthritis progression by decreasing the invasiveness of synovial fibroblasts and protecting cartilage, suggesting therapeutic benefits for RA (, 151). Additionally, EVs from human umbilical cord MSCs containing miR-451a inhibit the proliferation, migration, and invasion of RA synovial fibroblasts, improving arthritis in rat models (152). BMSC-derived EVs elevated miR-34a levels, reducing RA inflammation and inhibiting RA-FLS proliferation by targeting the cyclin I/p53/ataxia-telangiectasia mutated signaling pathway (153).
MSC-derived EVs infused with curcumin effectively regulate the proliferation and inflammatory response of RA-FLS, significantly reducing anti-apoptotic proteins and inflammatory mediators (154). EVs from IFN-β-primed MSCs also inhibit RA-FLS migration and surface marker expression, showing therapeutic potential for RA (). Additionally, transfected MSC EVs carrying the lncRNA HAND2-AS1 downregulate the pathogenic miR-143-3p, inhibiting RA-FLS proliferation and motility while inducing apoptosis in in vitro experiments (155).
A drug delivery system using adipose tissue-derived MSC EVs successfully delivered icariin to joints, reducing arthritis in rats with CIA by shifting macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 (156). These EVs enhanced therapeutic effectiveness by modulating macrophage diversity, especially when the MSCs were metabolically engineered to modify EV surface properties (157). Engineering modifications also improved the bone-targeting ability of MSC-EVs, reducing systemic side effects and increasing their clinical application potential (158).
5 Conclusion and future perspectives
EVs can modulate innate and adaptive immune responses in experimental RA models. They can transfer different noncoding RNA molecules that regulate gene expression of recipient cells. Molecular EV-cargos, including miRNAs, lncRNAs, mRNAs, and differentially expressed proteins, hold great potential as biomarkers for diagnosing RA. Additionally, MSC-EVs containing various types of miRNAs, lncRNAs, and circRNAs suppressed inflammation and the pathogenic activities of FLS in RA. EVs can also serve as carriers for existing medications. In summary, EVs can inhibit RA immunopathogenesis, reduce the disease’s progression, and serve as promising biomarkers for its diagnosis. Nonetheless, additional research including gene enrichment and pathway analysis is required to detect changes in key signaling pathways and immunoregulatory networks in immune cells exposed to EVs. This will help to completely unravel the molecular mechanisms underlying the immunomodulatory effects of EV cargos in RA.
Statements
Author contributions
DA: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. YA: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. AAd: Conceptualization, Writing – original draft, Writing – review & editing. ZT: Writing – review & editing. BT: Writing – review & editing. AF: Writing – review & editing. BS: Writing – review & editing. GA: Writing – review & editing. MG: Writing – review & editing. MJ: Writing – review & editing. TB: Writing – review & editing. AAt: Conceptualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
KalluriRLeBleuVS. The biology, function, and biomedical applications of exosomes. Science. (2020) 367(6478):. doi: 10.1126/science.aau6977
2
TianJCasellaGZhangYRostamiALiX. Potential roles of extracellular vesicles in the pathophysiology, diagnosis, and treatment of autoimmune diseases. Int J Biol Sci. (2020) 16:620–32. doi: 10.7150/ijbs.39629
3
BarileLVassalliG. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. (2017) 174:63–78. doi: 10.1016/j.pharmthera.2017.02.020
4
WuYFuHHaoJYangZQiaoXLiYet al. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer. Front Immunol. (2024) 15:1342728. doi: 10.3389/fimmu.2024.1342728
5
BakinowskaEKiełbowskiK. The role of extracellular vesicles in the pathogenesis and treatment of rheumatoid arthritis and osteoarthritis. Cells. (2023) 12(23):. doi: 10.3390/cells12232716
6
MorrisonTJJacksonMVCunninghamEKKissenpfennigAMcAuleyDFO'KaneCMet al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med. (2017) 196(10):1275–86. doi: 10.1164/rccm.201701-0170OC
7
SkotlandTSaginiKSandvigKLlorenteA. An emerging focus on lipids in extracellular vesicles. Adv Drug Delivery Rev. (2020) 159:308–21. doi: 10.1016/j.addr.2020.03.002
8
WelshJAGoberdhanDCI. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. (2024) 13(2):. doi: 10.1002/jev2.12416
9
VellaLJSciclunaBJ. A rigorous method to enrich for exosomes from brain tissue. J Extracell Vesicles. (2017) 6(1):1348885. doi: 10.1080/20013078.2017.1348885
10
AdmyreCJohanssonSMQaziKRFilénJJLahesmaaRNormanMet al. Exosomes with immune modulatory features are present in human breast milk. J Immunol. (2007) 179:1969–78. doi: 10.4049/jimmunol.179.3.1969
11
EsaAConnollyKDWilliamsRArcherCW. Extracellular vesicles in the synovial joint: is there a role in the pathophysiology of osteoarthritis? Malays Orthop J. (2019) 13:1–7. doi: 10.5704/MOJ.1903.012
12
HanPBartoldPM. Salivary outer membrane vesicles and DNA methylation of small extracellular vesicles as biomarkers for periodontal status: A pilot study. Int J Mol Sci. (2021) 22(5). doi: 10.3390/ijms22052423
13
WuAWolleyMJFentonRAStowasserM. Using human urinary extracellular vesicles to study physiological and pathophysiological states and regulation of the sodium chloride cotransporter. Front Endocrinol (Lausanne). (2022) 13:981317. doi: 10.3389/fendo.2022.981317
14
AlberroAIparraguirreL. Extracellular vesicles in blood: sources, effects, and applications. Int J Mol Sci. (2021) 22(15). doi: 10.3390/ijms22158163
15
AloiNDragoG. Extracellular vesicles and immunity: at the crossroads of cell communication. Int J Mol Sci. (2024) 25(2). doi: 10.3390/ijms25021205
16
BandiniSUliviPRossiT. Extracellular vesicles, circulating tumor cells, and immune checkpoint inhibitors: hints and promises. Cells. (2024) 13(4). doi: 10.3390/cells13040337
17
XieSZhangQJiangL. Current knowledge on exosome biogenesis, cargo-sorting mechanism and therapeutic implications. Membranes (Basel). (2022) 12(5). doi: 10.3390/membranes12050498
18
HanQFLiWJHuKSGaoJZhaiWLYangJHet al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. (2022) 21:207. doi: 10.1186/s12943-022-01671-0
19
LiS. The basic characteristics of extracellular vesicles and their potential application in bone sarcomas. J Nanobiotechnology. (2021) 19:277. doi: 10.1186/s12951-021-01028-7
20
LimHJYoonHKimHKangYWKimJEKimOYet al. Extracellular vesicle proteomes shed light on the evolutionary, interactive, and functional divergence of their biogenesis mechanisms. Front Cell Dev Biol. (2021) 9:734950. doi: 10.3389/fcell.2021.734950
21
BattistelliMFalcieriE. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biol (Basel). (2020) 9. doi: 10.3390/biology9010021
22
DieudéMBellCTurgeonJBeillevaireDPomerleauLYangBet al. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med. (2015) 7:318ra200. doi: 10.1126/scitranslmed.aac9816
23
JosephJRahmaniBColeYPuttaguntaNLinEKhanZKet al. Can soluble immune checkpoint molecules on exosomes mediate inflammation? J Neuroimmune Pharmacol. (2022) 17(3-4):381–97. doi: 10.1007/s11481-021-10018-3
24
YinZYuMMaTZhangCHuangSKarimzadehMRet al. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. (2021) 9(1). doi: 10.1136/jitc-2020-001698
25
WangMZhangB. The immunomodulation potential of exosomes in tumor microenvironment. J Immunol Res. (2021) 2021:3710372. doi: 10.1155/2021/3710372
26
JungIShinSBaekMC. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. (2024) 56(1):19–31. doi: 10.1038/s12276-023-01132-8
27
LyuCSunHSunZ. Roles of exosomes in immunotherapy for solid cancers. Cell Death Dis. (2024) 15(2):106. doi: 10.1038/s41419-024-06494-z
28
MaYZhouYZouSSSunY. Exosomes released from Sertoli cells contribute to the survival of Leydig cells through CCL20 in rats. Mol Hum Reprod. (2022) 28(2). doi: 10.1093/molehr/gaac002
29
ZhangBZhaoMLuQ. Extracellular vesicles in rheumatoid arthritis and systemic lupus erythematosus: functions and applications. Front Immunol. (2020) 11:575712. doi: 10.3389/fimmu.2020.575712
30
OvchinnikovaLAZalevskyAO. Extracellular vesicles in chronic demyelinating diseases: prospects in treatment and diagnosis of autoimmune neurological disorders. Life (Basel). (2022) 12(11). doi: 10.3390/life12111943
31
SuireCNHadeMD. Extracellular vesicles in type 1 diabetes: A versatile tool. Bioengineering (Basel). (2022) 9(3). doi: 10.3390/bioengineering9030105
32
SmolenJSAletahaDMcInnesIB. Rheumatoid arthritis. Lancet. (2016) 388:2023–38. doi: 10.1016/S0140-6736(16)30173-8
33
AletahaDSmolenJS. Diagnosis and management of rheumatoid arthritis: A review. Jama. (2018) 320:1360–72. doi: 10.1001/jama.2018.13103
34
AlcarazMJGuillénMI. Cellular and molecular targets of extracellular vesicles from mesenchymal stem/stromal cells in rheumatoid arthritis. Stem Cells Transl Med. (2022) 11:1177–85. doi: 10.1093/stcltm/szac075
35
LiuHLiRLiuTYangLYinGXieQ. Immunomodulatory effects of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles in rheumatoid arthritis. Front Immunol. (2020) 11:1912. doi: 10.3389/fimmu.2020.01912
36
FavalliEGRaimondoMGBeccioliniACrottiCBiggioggeroMCaporaliR. The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev. (2017) 16:1185–95. doi: 10.1016/j.autrev.2017.10.002
37
FeldmannMMainiRN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine. (2002) 69:12–8. doi: 10.1016/S1297-319X(01)00335-9
38
TianXWeiWCaoYAoTHuangFJavedRet al. Gingival mesenchymal stem cell-derived exosomes are immunosuppressive in preventing collagen-induced arthritis. J Cell Mol Med. (2022) 26(3):693–708. doi: 10.1111/jcmm.17086
39
MasoumiMAlesaeidiSKhorramdelazadHBehzadiMBaharlouRAlizadeh-FanalouSet al. Role of T cells in the pathogenesis of rheumatoid arthritis: focus on immunometabolism dysfunctions. Inflammation. (2023) 46:88–102. doi: 10.1007/s10753-022-01751-9
40
SinghABehlTSehgalASinghSSharmaNNavedTet al. Mechanistic insights into the role of B cells in rheumatoid arthritis. Int Immunopharmacol. (2021) 99:108078. doi: 10.1016/j.intimp.2021.108078
41
KuoDDingJ. HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med. (2019) 11(491). doi: 10.1126/scitranslmed.aau8587
42
MinHKKimKWLeeSHKimHR. Roles of mast cells in rheumatoid arthritis. Korean J Intern Med. (2020) 35:12–24. doi: 10.3904/kjim.2019.271
43
YangPQianFYZhangMFXuALWangXJiangBPet al. Th17 cell pathogenicity and plasticity in rheumatoid arthritis. J Leukoc Biol. (2019) 106:1233–40. doi: 10.1002/JLB.4RU0619-197R
44
RossEADevittAJohnsonJR. Macrophages: the good, the bad, and the gluttony. Front Immunol. (2021) 12:708186. doi: 10.3389/fimmu.2021.708186
45
CheminKGerstnerCMalmströmV. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front Immunol. (2019) 10:353. doi: 10.3389/fimmu.2019.00353
46
LuoPWangP. Immunomodulatory role of T helper cells in rheumatoid arthritis: a comprehensive research review. Bone Joint Res. (2022) 11(7):426–38. doi: 10.1302/2046-3758.117.BJR-2021-0594.R1
47
SioutiEAndreakosE. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. (2019) 165:152–69. doi: 10.1016/j.bcp.2019.03.029
48
LiCHanYLuoXQianCLiYSuHet al. Immunomodulatory nano-preparations for rheumatoid arthritis. Drug Delivery. (2023) 30:9–19. doi: 10.1080/10717544.2022.2152136
49
JouybariMTMojtahediFBabaahmadiMFaeedMEslaminejadMBTaghiyarL. Advancements in extracellular vesicle targeted therapies for rheumatoid arthritis: insights into cellular origins, current perspectives, and emerging challenges. Stem Cell Res Ther. (2024) 15(1):276. doi: 10.1186/s13287-024-03887-x
50
LindenberghMFSStoorvogelW. Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu Rev Immunol. (2018) 36:435–59. doi: 10.1146/annurev-immunol-041015-055700
51
AhmedSFJasimSAPallathadkaHKaurHRenuka JyothiSBansalPet al. New Therapeutic Strategies for the Inflammatory Rheumatoid Arthritis Disease: Emphasizing Mesenchymal Stem Cells and Associated exo-miRNA or exo-lncRNA. Cell Biochem Biophys. (2024) 82:1599–611. doi: 10.1007/s12013-024-01316-7
52
Di TrapaniMBassiGMidoloMGattiAKamgaPTCassaroAet al. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep. (2016) 6:24120. doi: 10.1038/srep24120
53
ShenZHuangWLiuJTianJWangSRuiK. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol. (2021) 12:749192. doi: 10.3389/fimmu.2021.749192
54
LiuXWeiQLuLCuiSMaKZhangWet al. Immunomodulatory potential of mesenchymal stem cell-derived extracellular vesicles: Targeting immune cells. Front Immunol. (2023) 14:1094685. doi: 10.3389/fimmu.2023.1094685
55
LiaoHJHsuPN. Immunomodulatory effects of extracellular vesicles from mesenchymal stromal cells: Implication for therapeutic approach in autoimmune diseases. Kaohsiung J Med Sci. (2024) 40(6):520–9. doi: 10.1002/kjm2.12841
56
WangSLeiBZhangEGongPGuJHeLet al. Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: from basic to clinics. Int J Nanomedicine. (2022) 17:1757–81. doi: 10.2147/IJN.S355366
57
ChenZLarreginaATMorelliAE. Impact of extracellular vesicles on innate immunity. Curr Opin Organ Transplant. (2019) 24:670–8. doi: 10.1097/MOT.0000000000000701
58
YangSZhaoMJiaS. Macrophage: Key player in the pathogenesis of autoimmune diseases. Front Immunol. (2023) 14:1080310. doi: 10.3389/fimmu.2023.1080310
59
ArabpourMSaghazadehARezaeiN. Anti-inflammatory and M2 macrophage polarization-promoting effect of mesenchymal stem cell-derived exosomes. Int Immunopharmacol. (2021) 97:107823. doi: 10.1016/j.intimp.2021.107823
60
HarrellCRJovicicN. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. (2019) 8(12). doi: 10.3390/cells8121605
61
XuDet al. Exosome-encapsulated miR-6089 regulates inflammatory response via targeting TLR4. J Cell Physiol. (2019) 234(2):1502–11. doi: 10.1002/jcp.v234.2
62
KimHBackJHHanGLeeSJParkYEGuMBet al. Extracellular vesicle-guided in situ reprogramming of synovial macrophages for the treatment of rheumatoid arthritis. Biomaterials. (2022) 286:121578. doi: 10.1016/j.biomaterials.2022.121578
63
RhysHIDell'AccioFPitzalisCMooreANorlingLVPerrettiM. Neutrophil microvesicles from healthy control and rheumatoid arthritis patients prevent the inflammatory activation of macrophages. EBioMedicine. (2018) 29:60–9. doi: 10.1016/j.ebiom.2018.02.003
64
ZhangBLaiRC. Therapeutic efficacy of mesenchymal stem/stromal cell small extracellular vesicles in alleviating arthritic progression by restoring macrophage balance. Int J Mol Sci. (2023) 13. doi: 10.3390/biom13101501
65
HuangYLuDMaWLiuJNingQTangFet al. miR-223 in exosomes from bone marrow mesenchymal stem cells ameliorates rheumatoid arthritis via downregulation of NLRP3 expression in macrophages. Mol Immunol. (2022) 143:68–76. doi: 10.1016/j.molimm.2022.01.002
66
ReisMMavinENicholsonLGreenKDickinsonAMWangXN. Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front Immunol. (2018) 9:2538. doi: 10.3389/fimmu.2018.02538
67
PozsgayJSzekaneczZSármayG. Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol. (2017) 13:525–37. doi: 10.1038/nrrheum.2017.107
68
Rincón-ArévaloHBurbanoCAtehortúaLRojasMVanegas-GarcíaAVásquezGet al. Modulation of B cell activation by extracellular vesicles and potential alteration of this pathway in patients with rheumatoid arthritis. Arthritis Res Ther. (2022) 24(1):169. doi: 10.1186/s13075-022-02837-3
69
CosenzaSToupetKMaumusMLuz-CrawfordPBlanc-BrudeOJorgensenCet al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. (2018) 8:1399–410. doi: 10.7150/thno.21072
70
WuXZhuDTianJTangXGuoHMaJet al. Granulocytic myeloid-derived suppressor cell exosomal prostaglandin E2 ameliorates collagen-induced arthritis by enhancing IL-10(+) B cells. Front Immunol. (2020) 11:588500. doi: 10.3389/fimmu.2020.588500
71
ChenJShiXDengYDangJLiuYZhaoJet al. miRNA-148a-containing GMSC-derived EVs modulate Treg/Th17 balance via IKKB/NF-κB pathway and treat a rheumatoid arthritis model. JCI Insight. (2024) 9. doi: 10.1172/jci.insight.177841
72
ZhuDTianJWuXLiMTangXRuiKet al. G-MDSC-derived exosomes attenuate collagen-induced arthritis by impairing Th1 and Th17 cell responses. Biochim Biophys Acta Mol Basis Dis. (2019) 1865:165540. doi: 10.1016/j.bbadis.2019.165540
73
MaDXuKZhangGLiuYGaoJTianMet al. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int Immunopharmacol. (2019) 74:105687. doi: 10.1016/j.intimp.2019.105687
74
XuKMaDZhangGGaoJSuYLiuSet al. Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorate collagen-induced arthritis via immunomodulatory T lymphocytes. Mol Immunol. (2021) 135:36–44. doi: 10.1016/j.molimm.2021.04.001
75
FuYLiJZhangZRenFWangYJiaHet al. Umbilical cord mesenchymal stem cell-derived exosomes alleviate collagen-induced arthritis by balancing the population of Th17 and regulatory T cells. FEBS Lett. (2022) 596(20):2668–77. doi: 10.1002/1873-3468.14460
76
Franco da CunhaFAndrade-OliveiraVCandido de AlmeidaDBorges da SilvaTNaffah de Souza BredaCCosta CruzMet al. Extracellular vesicles isolated from mesenchymal stromal cells modulate CD4(+) T lymphocytes toward a regulatory profile. Cells. (2020) 9(4). doi: 10.3390/cells9041059
77
LeeSKimSChungHMoonJHKangSJParkCG. Mesenchymal stem cell-derived exosomes suppress proliferation of T cells by inducing cell cycle arrest through p27kip1/Cdk2 signaling. Immunol Lett. (2020) 225:16–22. doi: 10.1016/j.imlet.2020.06.006
78
RenZLiuXAbdollahiETavasolianF. Genetically engineered exosomes as a potential regulator of th1 cells response in rheumatoid arthritis. Biopreserv Biobank. (2023) 21(4):355–66. doi: 10.1089/bio.2022.0003
79
TavasolianFHosseiniAZSoudiSNaderiM. miRNA-146a improves immunomodulatory effects of MSC-derived exosomes in rheumatoid arthritis. Curr Gene Ther. (2020) 20:297–312. doi: 10.2174/1566523220666200916120708
80
HylandMMennanCDaviesR. Extracellular vesicles derived from umbilical cord mesenchymal stromal cells show enhanced anti-inflammatory properties via upregulation of miRNAs after pro-inflammatory priming. Stem Cell Rev Rep. (2023) 19(7):2391–406. doi: 10.1007/s12015-023-10586-2
81
KayAGTreadwellKRoachPMorganRLodgeRHylandM. Therapeutic effects of hypoxic and pro-inflammatory priming of mesenchymal stem cell-derived extracellular vesicles in inflammatory arthritis. Int J Mol Sci. (2021) 23(1). doi: 10.3390/ijms23010126
82
TsiapalisDFloudasA. Therapeutic effects of mesenchymal/stromal stem cells and their derived extracellular vesicles in rheumatoid arthritis. Sci Adv. (2023) 12:849–62. doi: 10.1093/stcltm/szad065
83
ChoiEWLimIRParkJHSongJChoiBKimS. Exosomes derived from mesenchymal stem cells primed with disease-condition-serum improved therapeutic efficacy in a mouse rheumatoid arthritis model via enhanced TGF-β1 production. Stem Cell Res Ther. (2023) 14:283. doi: 10.1186/s13287-023-03523-0
84
ChuXChenLZhangY. Exosomes derived from PMN-MDSCs preconditioned by hypoxia attenuate arthropathy of collagen-induced arthritis mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. (2021) 37:728–35.
85
LeeHIAhnMJYooJKAhnSHParkSYSeoHet al. Exosome-mediated delivery of super-repressor IκBα alleviates inflammation and joint damages in rheumatoid arthritis. Arthritis Res Ther. (2024) 26(1):2. doi: 10.1186/s13075-023-03225-1
86
ChenJHuangFHouYLinXLiangRHuXet al. TGF-β-induced CD4+ FoxP3+ regulatory T cell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model. Cell Mol Immunol. (2021) 18:2516–29. doi: 10.1038/s41423-021-00764-y
87
LinMLeiSChaiYXuJWangYWuCet al. Immunosuppressive microvesicles-mimetic derived from tolerant dendritic cells to target T-lymphocytes for inflammation diseases therapy. J Nanobiotechnology. (2024) 22:201. doi: 10.1186/s12951-024-02470-z
88
GreisenSRYanYHansenASVenøMTNyengaardJRMoestrupSKet al. Extracellular vesicles transfer the receptor programmed death-1 in rheumatoid arthritis. Front Immunol. (2017) 8:851. doi: 10.3389/fimmu.2017.00851
89
ShenoyGNBhattaM. Exosomes represent an immune suppressive T cell checkpoint in human chronic inflammatory microenvironments. Immunol Invest. (2020) 49(7):726–43. doi: 10.1080/08820139.2020.1748047
90
SchioppoTUbialiT. The role of extracellular vesicles in rheumatoid arthritis: a systematic review. Clin Rheumatol. (2021) 40(9):3481–97. doi: 10.1007/s10067-021-05614-w
91
ObaRIsomuraMIgarashiANagataK. Circulating CD3(+)HLA-DR(+) extracellular vesicles as a marker for th1/tc1-type immune responses. J Immunol Res. (2019) 2019:6720819. doi: 10.1155/2019/6720819
92
XueLWangBLiXZhuJWangWHuangFet al. Comprehensive analysis of serum exosome-derived lncRNAs and mRNAs from patients with rheumatoid arthritis. Arthritis Res Ther. (2023) 25:201. doi: 10.1186/s13075-023-03174-9
93
HeydariRKoohiFRasouliM. Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents. Vaccines (Basel). (2023) 11(3). doi: 10.3390/vaccines11030687
94
LiuHChenYYinGXieQ. Therapeutic prospects of MicroRNAs carried by mesenchymal stem cells-derived extracellular vesicles in autoimmune diseases. Life Sci. (2021) 277:119458. doi: 10.1016/j.lfs.2021.119458
95
LetonjaJPetrovičD. A review of microRNAs and lncRNAs in atherosclerosis as well as some major inflammatory conditions affecting atherosclerosis. Biomedicines. (2024) 12(6). doi: 10.3390/biomedicines12061322
96
MaedaYFarinaNHMatzelleMMFanningPJLianJBGravalleseEM. Synovium-derived microRNAs regulate bone pathways in rheumatoid arthritis. J Bone Miner Res. (2017) 32:461–72. doi: 10.1002/jbmr.3005
97
FoersAD. Extracellular vesicles in synovial fluid from rheumatoid arthritis patients contain miRNAs with capacity to modulate inflammation. Cell Mol Life Sci. (2021) 22. doi: 10.3390/ijms22094910
98
AdugnaAMucheYMelkamuAJemalMBelewHAmareGA. Current updates on the molecular and genetic signals as diagnostic and therapeutic targets for hepatitis B virus-associated hepatic Malignancy. Heliyon. (2024) 10:e34288. doi: 10.1016/j.heliyon.2024.e34288
99
LiNChenZFengWGongZLinCChenJet al. Triptolide improves chondrocyte proliferation and secretion via down-regulation of miR-221 in synovial cell exosomes. Phytomedicine. (2022) 107:154479. doi: 10.1016/j.phymed.2022.154479
100
MaunderDBrownPMBarron-MillarBLendremDWNaamaneNMacdonaldJet al. Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy. Rheumatology (Oxford). (2023) 63:2259–67. doi: 10.1093/rheumatology/kead104.155
101
YuYParkSLeeHKwonEJParkHRKimYHet al. Exosomal hsa-miR-335-5p and hsa-miR-483-5p are novel biomarkers for rheumatoid arthritis: A development and validation study. Int Immunopharmacol. (2023) 120:110286. doi: 10.1016/j.intimp.2023.110286
102
LimMKYooJSheenDHIhmCLeeSKKimSA. Serum exosomal miRNA-1915-3p is correlated with disease activity of korean rheumatoid arthritis. In Vivo. (2020) 34:2941–5. doi: 10.21873/invivo.12124
103
TakamuraYAokiWSatomuraAShibasakiSUedaM. Small RNAs detected in exosomes derived from the MH7A synovial fibroblast cell line with TNF-α stimulation. PLoS One. (2018) 13(8). doi: 10.1371/journal.pone.0201851
104
WielińskaJCrosslandRE. Exploring the extracellular vesicle microRNA expression repertoire in patients with rheumatoid arthritis and ankylosing spondylitis treated with TNF inhibitors. Dis Markers. (2021) 2021:2924935. doi: 10.1155/2021/2924935
105
Rodríguez-MuguruzaSAltuna-CoyACastro-OreiroSPoveda-ElicesMJFontova-GarroféRChacónMR. A Serum Biomarker Panel of exomiR-451a, exomiR-25-3p and Soluble TWEAK for Early Diagnosis of Rheumatoid Arthritis. Front Immunol. (2021) 12:790880. doi: 10.3389/fimmu.2021.790880
106
KarimiBDehghani FiroozabadiAPeymaniMGhaediK. Circulating long noncoding RNAs as novel bio-tools: Focus on autoimmune diseases. Hum Immunol. (2022) 83:618–27. doi: 10.1016/j.humimm.2022.06.001
107
SunSLiangLTianRHuangQJiZLiXet al. LncRNA expression profiling in exosomes derived from synovial fluid of patients with rheumatoid arthritis. Int Immunopharmacol. (2024) 130:111735. doi: 10.1016/j.intimp.2024.111735
108
LiGFangYXuNDingYLiuD. Fibroblast-like synoviocytes-derived exosomal circFTO deteriorates rheumatoid arthritis by enhancing N6-methyladenosine modification of SOX9 in chondrocytes. Arthritis Res Ther. (2024) 26:56. doi: 10.1186/s13075-024-03290-0
109
WuHChenQWangSYangCXuLXiaoHet al. Serum exosomes lncRNAs: TCONS_I2_00013502 and ENST00000363624 are new diagnostic markers for rheumatoid arthritis. Front Immunol. (2024) 15:1419683. doi: 10.3389/fimmu.2024.1419683
110
ShuaiZQWangZXRenJLYangXKXuB. Differential expressions and potential clinical values of lncRNAs in the plasma exosomes of rheumatoid arthritis. Int Immunopharmacol. (2024) 128:111511. doi: 10.1016/j.intimp.2024.111511
111
HuangYLiuYHuangQSunSJiZHuangLet al. TMT-based quantitative proteomics analysis of synovial fluid-derived exosomes in inflammatory arthritis. Front Immunol. (2022) 13:800902. doi: 10.3389/fimmu.2022.800902
112
NakamachiYUtoKHayashiSOkanoTMorinobuAKurodaRet al. Exosomes derived from synovial fibroblasts from patients with rheumatoid arthritis promote macrophage migration that can be suppressed by miR-124-3p. Heliyon. (2023) 9:e14986. doi: 10.1016/j.heliyon.2023.e14986
113
QinQSongR. Systemic proteomic analysis reveals distinct exosomal protein profiles in rheumatoid arthritis. J Immunol Res. (2021) 2021:9421720. doi: 10.1155/2021/9421720
114
HuangLLiangLJiZChenSLiuMHuangQet al. Proteomics profiling of CD4 + T-cell-derived exosomes from patients with rheumatoid arthritis. Int Immunopharmacol. (2023) 122:110560. doi: 10.1016/j.intimp.2023.110560
115
ArntzOJPietersBCHThurlingsRMWeninkMHvan LentPKoendersMIet al. Rheumatoid arthritis patients with circulating extracellular vesicles positive for igM rheumatoid factor have higher disease activity. Front Immunol. (2018) 9:2388. doi: 10.3389/fimmu.2018.02388
116
BurbanoCRojasMMuñoz-VahosCVanegas-GarcíaA. Extracellular vesicles are associated with the systemic inflammation of patients with seropositive rheumatoid arthritis. Sci Rep. (2018) 8. doi: 10.1038/s41598-018-36335-x
117
ArntzOJThurlingsRMBlaney DavidsonENJansenPVermeulenMKoendersMIet al. Profiling of plasma extracellular vesicles identifies proteins that strongly associate with patient's global assessment of disease activity in rheumatoid arthritis. Front Med (Lausanne). (2023) 10:1247778. doi: 10.3389/fmed.2023.1247778
118
UcciFMRecalchiSBarbatiCManganelliVCapozziARiitanoGet al. Citrullinated and carbamylated proteins in extracellular microvesicles from plasma of patients with rheumatoid arthritis. Rheumatol (Oxford). (2023) 62:2312–9. doi: 10.1093/rheumatology/keac598
119
BuzasEI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. (2023) 23:236–50. doi: 10.1038/s41577-022-00763-8
120
CurranAMGirgisAA. Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis. Nat Commun. (2023) 14(1):1061. doi: 10.1038/s41467-023-36620-y
121
van DelftMAMHuizingaTWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. (2020) 110:102392. doi: 10.1016/j.jaut.2019.102392
122
RiitanoGRecalchiSCapozziAManganelliVMisasiRGarofaloT. The role of autophagy as a trigger of post-translational modifications of proteins and extracellular vesicles in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. (2023) 24(16). doi: 10.3390/ijms241612764
123
VomeroMBarbatiCColasantiTPerriconeCNovelliLCeccarelliFet al. Autophagy and rheumatoid arthritis: current knowledges and future perspectives. Front Immunol. (2018) 9:1577. doi: 10.3389/fimmu.2018.01577
124
SugawaraEKatoMKudoYLeeW. Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. Autophagy. (2020) 16(5):946–55. doi: 10.1080/15548627.2019.1664144
125
GudbergssonJMJohnsenKB. Exosomes and autophagy: rekindling the vesicular waste hypothesis. J Cell Commun Signal. (2019) 13:443–50. doi: 10.1007/s12079-019-00524-8
126
AlghamdiMAlamrySABahlasSMUverskyVNRedwanEM. Circulating extracellular vesicles and rheumatoid arthritis: a proteomic analysis. Cell Mol Life Sci. (2021) 79(1):25. doi: 10.1007/s00018-021-04020-4
127
WuLFZhangQMoXBLinJWuYLLuXet al. Identification of novel rheumatoid arthritis-associated MiRNA-204-5p from plasma exosomes. Exp Mol Med. (2022) 54:334–45. doi: 10.1038/s12276-022-00751-x
128
LuJWuJZhangXZhongRWangBYangHet al. Characterization of the MicroRNA profile in rheumatoid arthritis plasma exosomes and their roles in B-cell responses. Clinics (Sao Paulo). (2024) 79:100441. doi: 10.1016/j.clinsp.2024.100441
129
GongJZhangXKhanALiangJXiongTYangPet al. Identification of serum exosomal miRNA biomarkers for diagnosis of Rheumatoid arthritis. Int Immunopharmacol. (2024) 129:111604. doi: 10.1016/j.intimp.2024.111604
130
HuldaniHAbdalkareem JasimSOlegovich BokovDAbdelbassetWKNader ShalabyMThangaveluLet al. Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases. Int Immunopharmacol. (2022) 106:108634. doi: 10.1016/j.intimp.2022.108634
131
FuHHuDZhangLTangP. Role of extracellular vesicles in rheumatoid arthritis. Clin Rheumatol. (2018) 93:125–32. doi: 10.1016/j.molimm.2017.11.016
132
YanFZhongZWangYFengYMeiZLiHet al. Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis. J Nanobiotechnology. (2020) 18:115. doi: 10.1186/s12951-020-00675-6
133
YangXXiaHLiuCWuYLiuXChengYet al. The novel delivery-exosome application for diagnosis and treatment of rheumatoid arthritis. Pathol Res Pract. (2023) 242:154332. doi: 10.1016/j.prp.2023.154332
134
LiuHChenYHuangYWeiLRanJLiQet al. Macrophage-derived mir-100-5p orchestrates synovial proliferation and inflammation in rheumatoid arthritis through mTOR signaling. J Nanobiotechnology. (2024) 22:197. doi: 10.1186/s12951-024-02444-1
135
LiHFengYZhengXJiaMMeiZWangYet al. M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release. (2022) 341:16–30. doi: 10.1016/j.jconrel.2021.11.019
136
TakenakaMYabutaATakahashiYTakakuraY. Interleukin-4-carrying small extracellular vesicles with a high potential as anti-inflammatory therapeutics based on modulation of macrophage function. Biomaterials. (2021) 278:121160. doi: 10.1016/j.biomaterials.2021.121160
137
TangYWuZGuoRHuangJRongXZhuBet al. Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis. J Mater Chem B. (2022) 10(38):7862–74. doi: 10.1039/D2TB01219G
138
ZhaoCSongWMaJWangN. Macrophage-derived hybrid exosome-mimic nanovesicles loaded with black phosphorus for multimodal rheumatoid arthritis therapy. Biomater Sci. (2022) 10:6731–9. doi: 10.1039/D2BM01274J
139
LiXLiSFuXWangY. Apoptotic extracellular vesicles restore homeostasis of the articular microenvironment for the treatment of rheumatoid arthritis. Cells. (2024) 35:564–76. doi: 10.1016/j.bioactmat.2023.11.019
140
KimSHLechmanERBiancoNMenonRKeravalaANashJet al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. (2005) 174:6440–8. doi: 10.4049/jimmunol.174.10.6440
141
BiancoNRKimSHRuffnerMARobbinsPD. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum. (2009) 60:380–9. doi: 10.1002/art.24229
142
ShinTHKimHSKangTWLeeBCLeeHYKimYJet al. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis. Cell Death Dis. (2016) 7:e2524. doi: 10.1038/cddis.2016.442
143
PistoiaVRaffaghelloL. Mesenchymal stromal cells and autoimmunity. Int Immunol. (2017) 29:49–58. doi: 10.1093/intimm/dxx008
144
YangJHLiuFXWangJHChengMWangSFXuDH. Mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles: Potential roles in rheumatic diseases. World J Stem Cells. (2020) 12:688–705. doi: 10.4252/wjsc.v12.i7.688
145
Martinez-ArroyoOOrtegaA. Mesenchymal stem cell-derived extracellular vesicles as non-coding RNA therapeutic vehicles in autoimmune diseases. Pharmaceutics. (2022) 14(4). doi: 10.3390/pharmaceutics14040733
146
KimIKKimSHChoiSMYounBSKimHS. Extracellular vesicles as drug delivery vehicles for rheumatoid arthritis. Stem Cells Transl Med. (2016) 11:329–42. doi: 10.2174/1574888X11666151203223251
147
LiuSXuXLiangSChenZZhangYQianAet al. The application of MSCs-derived extracellular vesicles in bone disorders: novel cell-free therapeutic strategy. Front Cell Dev Biol. (2020) 8:619. doi: 10.3389/fcell.2020.00619
148
ZhangYJiaoZWangS. Bone marrow mesenchymal stem cells release miR-378a-5p-carried extracellular vesicles to alleviate rheumatoid arthritis. J Innate Immun. (2023) 15:893–910. doi: 10.1159/000534830
149
YouSKohJHLengLKimWUBucalaR. The tumor-like phenotype of rheumatoid synovium: molecular profiling and prospects for precision medicine. Arthritis Rheumatol. (2018) 70:637–52. doi: 10.1002/art.40406
150
PrattAGSiebertSColeMStockenDDYapCKellySet al. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatol. (2021) 3:e337–46. doi: 10.1016/S2665-9913(21)00061-8
151
BrucknerSCapriaVMZenoBLeblebiciogluBGoyalKVasileffWKet al. The therapeutic effects of gingival mesenchymal stem cells and their exosomes in a chimeric model of rheumatoid arthritis. Arthritis Res Ther. (2023) 25:211. doi: 10.1186/s13075-023-03185-6
152
MiLGaoJLiNLiuYZhangNGaoYet al. Human umbilical cord mesenchymal stem cell-derived exosomes loaded miR-451a targets ATF2 to improve rheumatoid arthritis. Int Immunopharmacol. (2024) 127:111365. doi: 10.1016/j.intimp.2023.111365
153
WuHZhouXWangX. miR-34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis. J Cell Mol Med. (2021) 25(4):1896–910. doi: 10.1111/jcmm.15857
154
HeXZhangCAmirsaadatSJalilATKadhimMMAbasiMet al. Curcumin-loaded mesenchymal stem cell-derived exosomes efficiently attenuate proliferation and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Appl Biochem Biotechnol. (2023) 195:51–67. doi: 10.1007/s12010-022-04090-5
155
SuYLiuYMaCGuanCMaXMengS. Mesenchymal stem cell-originated exosomal lncRNA HAND2-AS1 impairs rheumatoid arthritis fibroblast-like synoviocyte activation through miR-143-3p/TNFAIP3/NF-κB pathway. J Orthop Surg Res. (2021) 16:116. doi: 10.1186/s13018-021-02248-1
156
YanQLiuHSunSYangYFanDYangYet al. Adipose-derived stem cell exosomes loaded with icariin alleviates rheumatoid arthritis by modulating macrophage polarization in rats. J Nanobiotechnology. (2024) 22:423. doi: 10.1186/s12951-024-02711-1
157
YouDG. Metabolically engineered stem cell-derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis. Int J Mol Sci. (2021) 7. doi: 10.1126/sciadv.abe0083
158
TangJWangXLinXWuC. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases. Cell Death Discov. (2024) 10(1):212. doi: 10.1038/s41420-024-01973-w
159
ChenZWangHXiaY. Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J Immunol. (2018) 201(8):2472–82. doi: 10.4049/jimmunol.1800304
160
LiGQFangYXLiuYMengFRWuXZhangCWet al. MicroRNA-21 from bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. Ther Adv Chronic Dis. (2021) 12:20406223211007369. doi: 10.1177/20406223211007369
161
ChangLKanL. Mesenchymal Stem Cell-Originated Exosomal Circular RNA circFBXW7 Attenuates Cell Proliferation, Migration and Inflammation of Fibroblast-Like Synoviocytes by Targeting miR-216a-3p/HDAC4 in Rheumatoid Arthritis. J Inflammation Res. (2021) 14:6157–71. doi: 10.2147/JIR.S336099
162
MaWTangFXiaoLHanSYaoXZhangQet al. miR-205-5p in exosomes divided from chondrogenic mesenchymal stem cells alleviated rheumatoid arthritis via regulating MDM2 in fibroblast-like synoviocytes. J Musculoskelet Neuronal Interact. (2022) 22:132–41.
163
MengQQiuB. Exosomal microRNA-320a derived from mesenchymal stem cells regulates rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing CXCL9 expression. Front Physiol. (2020) 11:441. doi: 10.3389/fphys.2020.00441
164
ZhangJZhangYMaYLuoLChuMZhangZ. Therapeutic Potential of Exosomal circRNA Derived from Synovial Mesenchymal Cells via Targeting circEDIL3/miR-485-3p/PIAS3/STAT3/VEGF Functional Module in Rheumatoid Arthritis. Int J Nanomedicine. (2021) 16:7977–94. doi: 10.2147/IJN.S333465
165
LiuDFangYRaoYTanWZhouWWuXet al. Synovial fibroblast-derived exosomal microRNA-106b suppresses chondrocyte proliferation and migration in rheumatoid arthritis via down-regulation of PDK4. J Mol Med (Berl). (2020) 98(3):409–23. doi: 10.1007/s00109-020-01882-2
166
LinZLiWWangYLangXSunWZhuXet al. SMSCs-derived sEV overexpressing miR-433-3p inhibits angiogenesis induced by sEV released from synoviocytes under triggering of ferroptosis. Int Immunopharmacol. (2023) 116:109875. doi: 10.1016/j.intimp.2023.109875
167
RenJZhangFZhuSZhangWHouJHeRet al. Exosomal long non-coding RNA TRAFD1-4:1 derived from fibroblast-like synoviocytes suppresses chondrocyte proliferation and migration by degrading cartilage extracellular matrix in rheumatoid arthritis. Exp Cell Res. (2023) 422:113441. doi: 10.1016/j.yexcr.2022.113441
168
XuWLiuXQuWWangXSuHLiWet al. Exosomes derived from fibrinogen-like protein 1-overexpressing bone marrow-derived mesenchymal stem cells ameliorates rheumatoid arthritis. Bioengineered. (2022) 13(6):14545–61. doi: 10.1080/21655979.2022.2090379
169
ChenJLiuMLuoXPengLZhaoZHeCet al. Exosomal miRNA-486-5p derived from rheumatoid arthritis fibroblast-like synoviocytes induces osteoblast differentiation through the Tob1/BMP/Smad pathway. Biomater Sci. (2020) 8:3430–42. doi: 10.1039/C9BM01761E
170
HuangYChenLChenDFanPYuH. Exosomal microRNA-140-3p from human umbilical cord mesenchymal stem cells attenuates joint injury of rats with rheumatoid arthritis by silencing SGK1. Mol Med. (2022) 28(1):36. doi: 10.1186/s10020-022-00451-2
171
MengHYChenLQChenLH. The inhibition by human MSCs-derived miRNA-124a overexpression exosomes in the proliferation and migration of rheumatoid arthritis-related fibroblast-like synoviocyte cell. BMC Musculoskelet Disord. (2020) 21:150. doi: 10.1186/s12891-020-3159-y
Summary
Keywords
extracellular vesicles, immunomodulation, rheumatoid arthritis, therapeutic roles, diagnostic markers
Citation
Abebaw D, Akelew Y, Adugna A, Teffera ZH, Tegegne BA, Fenta A, Selabat B, Amare GA, Getinet M, Jemal M, Baylie T and Atnaf A (2024) Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis. Front. Immunol. 15:1499929. doi: 10.3389/fimmu.2024.1499929
Received
22 September 2024
Accepted
30 October 2024
Published
18 November 2024
Volume
15 - 2024
Edited by
Giacomo Cafaro, University of Perugia, Italy
Reviewed by
Gloria Riitano, Sapienza University of Rome, Italy
Onno Arntz, Radboud University Medical Centre, Netherlands
Updates
Copyright
© 2024 Abebaw, Akelew, Adugna, Teffera, Tegegne, Fenta, Selabat, Amare, Getinet, Jemal, Baylie and Atnaf.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Desalegn Abebaw, Desalegnabebaw20@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.